Patent · US Active

Kinase modulation, and indications therefor

US9814714B2 · kind B2 · utility

21Cited by
8References
31Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 20, 2016
Grant dateNov 14, 2017
Priority date—
Expiry dateMay 20, 2036

Classification

  • Technology area (CPC A)Human Necessities
  • CPC primaryA61P35/04
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.